B7-33 is a single-chain relaxin-2 B-chain analogue studied as a functionally selective RXFP1 agonist. The cited work covers receptor pharmacology, preclinical vascular models and myocardial-infarction-related remodeling in mice; it does not establish human efficacy. The price list contains three materially different labels: 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). It does not state the dosage unit, full sequence or terminal modifications, so those details must be resolved for each quote.
| Class | Single-chain relaxin-2 B-chain analogue studied as a functionally selective RXFP1 agonist. |
| Exact analog identity | The quote must state the full sequence, N- and C-terminal modifications, counterion and calculated mass; the class name alone is incomplete. |
| Listed presentations | 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). The dosage unit is not stated. |
| Identity evidence | Request batch LC-MS or an equivalent identity method and reconcile the observed mass with the exact quoted construct. |
| Content and impurities | Verify chromatographic area purity, net peptide content, related substances, water and residual solvents for the allocated lot. |
| Handling | Use the buffer, concentration, storage and in-use window supported for the exact supplied form and planned RXFP1 assay. |
Wholesale from $3.06
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 2 / Injectable (Lyophilized Powder) | $4.08 | $3.57 | $3.06 |
| 5 / Powder | $6.80 | $5.95 | $5.10 |
| 6 / Injectable (Lyophilized Powder) | $7.48 | $6.54 | $5.61 |
The class description “single-chain relaxin-2 B-chain analogue” does not fully identify a B7-33 material. The sequence, termini and exact supplied form determine whether a quote matches a published construct or assay.
Request the full sequence, terminal modifications, counterion, calculated mass and batch identity result. Reconcile every quoted presentation with that same construct definition.
Review the identity result, HPLC method and chromatogram, net peptide content, related substances, water and residual-solvent data for the allocated lot.
Specify the RXFP1 assay format, buffer constraints, concentration range, vial fill and handling window. Literature-derived activity cannot replace a batch-specific qualification result.
The cited studies report model- and construct-specific preclinical findings. They do not establish human efficacy or safety and do not verify an independently supplied lot.
Hossain et al. (2016). A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chemical Science. DOI: 10.1039/C5SC04754D
Study scope: RXFP1 signaling and pharmacology experiments performed with the paper's defined B7-33 construct. The single-chain relaxin-2 B-chain analogue defined and used in the reported experimental systems.
What it supports: Supports describing B7-33 as a functionally selective RXFP1 agonist within the study's receptor and signaling experiments.
Boundary: The paper does not establish clinical efficacy, interchangeability among unspecified analogs, or identity of a supplier batch.
Sarwar et al. (2017). B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). European Journal of Pharmacology. DOI: 10.1016/j.ejphar.2017.05.005
Study scope: Rat and mouse vascular preparations used to compare the defined B7-33 construct with human relaxin-2 or serelaxin. Study-defined B7-33 material, doses and experimental preparations.
What it supports: Supports a bounded statement about vascular-response observations in the reported rat and mouse models.
Boundary: The findings do not prove human vasoprotection, a therapeutic dose, or performance of an independently sourced lot.
Martin et al. (2020). B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice. Journal of the American Heart Association. DOI: 10.1161/JAHA.119.015748
Study scope: Mice in a myocardial-infarction-related adverse cardiac-remodeling model. The B7-33 construct, route and dose used in the reported mouse protocol.
What it supports: Supports discussing adverse cardiac-remodeling findings only within that mouse model.
Boundary: A mouse outcome does not establish human cardiovascular efficacy, safety or equivalence with a commercial batch.
B7-33 is a single-chain relaxin-2 B-chain analogue studied at the RXFP1 receptor. A quote must still identify the exact sequence and terminal modifications.
It describes the signaling behavior reported for the defined B7-33 construct in receptor experiments. It is not a claim of established therapeutic selectivity in people.
The price list contains 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). The dosage unit is not stated.
No. The cited vascular work is preclinical and the cardiac-remodeling paper reports a mouse model. Neither establishes human efficacy or safety.
Each of the three B7-33 forms has separate 10+, 25+ and 50+ per-SKU tiers. Published tiers apply when the order reaches 100+ total units; smaller total orders are quoted separately.
Confirm the full construct, observed mass, identity method, chromatographic area purity, net peptide content, impurities, supplied form and assay-specific handling instructions.